Market Overview

Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth


Sunesis Pharmaceuticals, Inc.'s (NASDAQ: SNSS) failed cancer drug vosaroxin offers no reason for investors to give up hope on other companies' potential cures, an analyst said Tuesday.

Sunesis said Tuesday its vosaroxin drug for acute myeloid leukemia failed to show effectiveness in a trial with nearly 800 patients. The company's shares opened Tuesday down about 80 percent from the preceding closing price.

But Roth analyst Joseph Pantginis prescribed several other companies touting unproven treatments for the blood disease, which accounts for about 1.2 percent of U.S. cancer deaths annually.

Their drugs, Pantginis said, are "using differentiated mechanisms of action." In other words, they're not the same as vosaroxin which was supposed to act on a DNA-related enzyme.

MEI Pharma Inc., for example, wants to apply pracinostat, a compound historically used by psychiatrists for mood disorders, as a means of treating leukemia by inhibiting an entirely different DNA-related enzyme.

Celator Pharmaceuticals Inc.'s CPX-351 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of the disorder. It's an injectable combination of cytarabine and daunorubicin.

Also, Stemline Therapeutics Inc.'s SL-401 showed promise against leukemia in a recent Phase I-II study.

And Aptose Biosciences Inc. is planning a Phase 1b clinical study of its APTO-253 leukimia treatment, followed by two disease-specific expansions planned in adults with hematologic malignancies in 2014.

Latest Ratings for SNSS

Dec 2018Initiates Coverage OnNeutral
Dec 2017UpgradesMarket PerformOutperform
Dec 2017DowngradesOutperformMarket Perform

View More Analyst Ratings for SNSS
View the Latest Analyst Ratings

Posted-In: Joseph Pantginis RothAnalyst Color News FDA Analyst Ratings


Related Articles (SNSS)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Eagle Bancorp Announces Receipt Of Regulatory Approvals For Merger With Virginia Heritage Bank

Dun & Bradstreet and Lattice Engines Announce Strategic Partnership to Help Businesses Source Leads And Deliver Measurable ROI